Literature DB >> 15278753

Oral enzyme combination versus diclofenac in the treatment of osteoarthritis of the knee--a double-blind prospective randomized study.

Naseer M Akhtar1, Rizwan Naseer, Abid Z Farooqi, Wajahat Aziz, Mussadeq Nazir.   

Abstract

The aim of this study was to compare the efficacy and safety of an oral enzyme-rutosid combination (ERC) containing rutosid and the enzymes bromelain and trypsin, with that of diclofenac in patients with osteoarthritis (OA) of the knee. A total of 103 patients presenting with painful episodes of OA of the knee were treated for 6 weeks in two study centers in a randomized, double-blind, parallel group trial. Altogether, 52 patients were treated in the ERC group and 51 patients were treated in the diclofenac group. Primary efficacy criteria were Lequesne's Algofunctional Index (LFI) and a 'complaint index', including pain at rest, pain on motion and restricted function. The efficacy criteria were analyzed by applying the Wilcoxon-Mann-Whitney test that provides the Mann-Whitney estimator (MW) as a measure of relevance. Non-inferiority was considered to be proven if the lower bound of the 97.5% one-sided confidence interval (CI-LB) was higher than MW = 0.36 (benchmark of not yet relevant inferiority). Both treatments resulted in clear improvements. Within the 6-week observation period, the mean value of the LFI decreased from 13.0 to 9.4 in the ERC group and from 12.5 to 9.4 in the diclofenac group. Non-inferiority of ERC was demonstrated by both primary criteria, LFI (MW = 0.5305; CI-LB = 0.4171) and complaint index (MW = 0.5434; CI-LB = 0.4296). Considerable improvements were also seen in secondary efficacy criteria, with a slight tendency towards superiority of ERC. The global judgment of efficacy by physician resulted in at least good ratings for 51.4% of the ERC patients, and for 37.2% of the diclofenac patients. In the majority of patients tolerability was judged in both drug groups as very good or good. The current study indicates that ERC can be considered as an effective and safe alternative to NSAIDs such as diclofenac in the treatment of painful episodes of OA of the knee. Placebo-controlled studies are now needed to confirm these results.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15278753     DOI: 10.1007/s10067-004-0902-y

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  10 in total

Review 1.  Osteoarthritis, an inflammatory disease: potential implication for the selection of new therapeutic targets.

Authors:  J P Pelletier; J Martel-Pelletier; S B Abramson
Journal:  Arthritis Rheum       Date:  2001-06

2.  Measuring gain in the evaluation of medical technology. The probability of a better outcome.

Authors:  G A Colditz; J N Miller; F Mosteller
Journal:  Int J Technol Assess Health Care       Date:  1988       Impact factor: 2.188

3.  [Comparative epidemiological study in patients with rheumatic diseases illustrated in a example of a treatment with non-steroidal anti- inflammatory drugs versus an oral enzyme combination preparation].

Authors:  A Wittenborg; P R Bock; J Hanisch; R Saller; B Schneider
Journal:  Arzneimittelforschung       Date:  2000-08

Review 4.  Use and benefits of nonsteroidal anti-inflammatory drugs.

Authors:  P Brooks
Journal:  Am J Med       Date:  1998-03-30       Impact factor: 4.965

5.  Indexes of severity for osteoarthritis of the hip and knee. Validation--value in comparison with other assessment tests.

Authors:  M G Lequesne; C Mery; M Samson; P Gerard
Journal:  Scand J Rheumatol Suppl       Date:  1987

Review 6.  Nonsteroidal anti-inflammatory drug gastropathy. Recognition and response.

Authors:  S H Roth; R E Bennett
Journal:  Arch Intern Med       Date:  1987-12

Review 7.  Response criteria for clinical trials on osteoarthritis of the knee and hip: a report of the Osteoarthritis Research Society International Standing Committee for Clinical Trials response criteria initiative.

Authors:  M Dougados; P Leclaire; D van der Heijde; D A Bloch; N Bellamy; R D Altman
Journal:  Osteoarthritis Cartilage       Date:  2000-11       Impact factor: 6.576

8.  [Oxaprozin versus diclofenac retard in treated of activated arthrosis].

Authors:  A Karbowski; M Schwitalle; A Eckardt
Journal:  Z Rheumatol       Date:  1998-04       Impact factor: 1.372

9.  Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs.

Authors:  M J Langman; J Weil; P Wainwright; D H Lawson; M D Rawlins; R F Logan; M Murphy; M P Vessey; D G Colin-Jones
Journal:  Lancet       Date:  1994-04-30       Impact factor: 79.321

Review 10.  Clinical evidence for osteoarthritis as an inflammatory disease.

Authors:  T Pincus
Journal:  Curr Rheumatol Rep       Date:  2001-12       Impact factor: 4.686

  10 in total
  13 in total

1.  Bromelain's penetration into the blood and sinonasal mucosa in patients with chronic rhinosinusitis.

Authors:  D Passali; G C Passali; L M Bellussi; C Sarafoleanu; M Loglisci; C Manea; C Iosif; F M Passali
Journal:  Acta Otorhinolaryngol Ital       Date:  2018-06       Impact factor: 2.124

2.  Bromelain treatment decreases neutrophil migration to sites of inflammation.

Authors:  David J Fitzhugh; Siqing Shan; Mark W Dewhirst; Laura P Hale
Journal:  Clin Immunol       Date:  2008-05-14       Impact factor: 3.969

3.  Efficacy of Bromelain along with Trypsin, Rutoside Trihydrate Enzymes and Diclofenac Sodium Combination Therapy for the treatment of TMJ Osteoarthritis - A Randomised Clinical Trial.

Authors:  S Jayachandran; Priyanka Khobre
Journal:  J Clin Diagn Res       Date:  2017-06-01

Review 4.  Osteoarthritis and nutrition. From nutraceuticals to functional foods: a systematic review of the scientific evidence.

Authors:  Laurent G Ameye; Winnie S S Chee
Journal:  Arthritis Res Ther       Date:  2006       Impact factor: 5.156

5.  Plant proteolytic enzyme papain abrogates angiogenic activation of human umbilical vein endothelial cells (HUVEC) in vitro.

Authors:  Thomas Mohr; Lucia Desser
Journal:  BMC Complement Altern Med       Date:  2013-09-21       Impact factor: 3.659

6.  The safety and efficacy of an enzyme combination in managing knee osteoarthritis pain in adults: a randomized, double-blind, placebo-controlled trial.

Authors:  Wolfgang W Bolten; Michael J Glade; Sonja Raum; Barry W Ritz
Journal:  Arthritis       Date:  2015-01-31

7.  Efficacy, tolerability, and safety of an oral enzyme combination vs diclofenac in osteoarthritis of the knee: results of an individual patient-level pooled reanalysis of data from six randomized controlled trials.

Authors:  Michael A Ueberall; Gerhard Hh Mueller-Schwefe; Rainer Wigand; Ute Essner
Journal:  J Pain Res       Date:  2016-11-04       Impact factor: 3.133

8.  Enhancement of the Anti-inflammatory Effect of Bromelain by Its Immobilization on Probiotic Spore of Bacillus cereus.

Authors:  Chika Jude Ugwuodo; Tochukwu Nwamaka T Nwagu; Tochukwu Thaddeus Ugwu; Chukwudi Ogbonnaya Onwosi
Journal:  Probiotics Antimicrob Proteins       Date:  2020-11-06       Impact factor: 4.609

9.  Properties and therapeutic application of bromelain: a review.

Authors:  Rajendra Pavan; Sapna Jain; Ajay Kumar
Journal:  Biotechnol Res Int       Date:  2012-12-10

10.  The effects of oral hydrolytic enzymes and flavonoids on inflammatory markers and coagulation after marathon running: study protocol for a randomized, double-blind, placebo-controlled trial.

Authors:  Viola Grabs; David C Nieman; Bernhard Haller; Martin Halle; Johannes Scherr
Journal:  BMC Sports Sci Med Rehabil       Date:  2014-02-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.